Urogen Pharma FCF per Share
The Free Cash Flow per Share of Urogen Pharma (URGN) as of Nov 2, 2026 is -3.31 USD. In the previous year, Free Cash Flow per Share was -2.06 USD — a change of 60.17% (lower).
Get this data via API
Financial Data API
FCF per Share
-3.31USD
YoY
60.17%
Last updated:
The Urogen Pharma FCF per Share history
3 Years
10 Years
25 Years
Max
| YEAR | FCF per Share | YoY |
|---|---|---|
| -3.31USD | +60.17% | |
| -2.06USD | -2.56% | |
| -2.12USD | -44.31% | |
| -3.80USD | -0.38% | |
| -3.82USD | -21.06% | |
| -4.84USD | +43.42% | |
| -3.37USD | +44.26% | |
| -2.34USD | +223.29% | |
| -0.72USD | -326.80% | |
| 0.32USD | -109.81% | |
| -3.25USD | +80.54% | |
| -1.80USD | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Urogen Pharma Stock analysis
Frequently Asked Questions about Urogen Pharma stock
Free Cash Flow per Share of Urogen Pharma is -3.31 USD in 2025.
Free Cash Flow per Share of Urogen Pharma changed from -2.06 USD to -3.31 USD, representing a 60.17% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of Free Cash Flow per Share Urogen Pharma since 2006 – with annual values, charts, and detailed analysis.
FCF per share measures the free cash flow allocated to each outstanding share. It is a key metric for assessing shareholder value creation.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Cash Flow — Urogen Pharma
All Key Metrics — Urogen Pharma
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth